Evidence map›Paper›PMID 40942154›Full record

ArticleMolecules (Basel, Switzerland)2025

Ni-Catalyzed [2 + 2 + 2] Cycloaddition via the Capture of Azametallacyclopentadienes with Allyl Boronate: Facile Access to Fused Pyridine Derivatives.

Kesi Du, Tao Zhu, Guangyu Li, Taohong Shi, Chunsheng Li, Siting Hu, Ruiran Gao, Zhao-Yang Wang, Jiuzhong Huang

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kesi DuGuizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China.
Tao ZhuJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, School of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
Guangyu LiJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, School of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
Taohong ShiJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, School of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
Chunsheng LiSchool of Environmental and Chemical Engineering, Zhaoqing University, Zhaoqing 526061, China.
Siting HuSchool of Environmental and Chemical Engineering, Zhaoqing University, Zhaoqing 526061, China.
Ruiran GaoGuizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China.
Zhao-Yang WangSchool of Chemistry, South China Normal University, Guangzhou 510006, China.ORCID 0000-0002-2391-5938
Jiuzhong HuangJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, School of Pharmacy, Gannan Medical University, Ganzhou 341000, China.ORCID 0000-0002-6474-7707

Funding

Guizhou Province Science and Technology Support Program QKHZC-[2025]YB133Jiangxi Provincial Natural Science Foundation 20242BAB25591National Natural Science Foundation of China 22361003Zhaoqing University Innovative Research Team Funding TD202413
6 · The paper itself

Abstract

An unprecedented nickel-catalyzed [2 + 2 + 2] cycloaddition that enables efficient construction of fused pyridine frameworks with allyl boronate was reported. This transformation is proposed to occur through a mechanism involving aza-nickelacyclopentadiene intermediates, wherein the boryl group of the allyl boronate plays a critical role in enabling the following cyclization via the control experiments. This work not only expands the structural diversity accessible via transition-metal-catalyzed [2 + 2 + 2] cycloadditions but also showcases the untapped potential of unsaturated substrates in cycloaddition reactions.

Indexed as

[2 + 2 + 2] cycloadditionallyl boronateazanickelcyclopentadienefused pyridine derivativesnickel catalysis

Identifiers

PMID40942154
PMCPMC12430644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.